Latest News

Biopharma Launches Clinical Trial of Primary Asset in Endometrial Cancer

December 7, 2021 (Investorideas.com Newswire) “Solid tumors offers a substantial opportunity for Karyopharm Therapeutics’ Xpovio (selinexor) that perhaps investors have not yet realized,”

You may also like

Leave a reply

Your email address will not be published.

More in Latest News